8月20日，诺华盘中上涨3.11%，报159.35美元/股，成交额2.23亿美元。消息面上，诺华近期在英国法院赢得Entresto专利挑战，法院裁定其专利及补充保护证书有效，Accord Healthcare的仿制药计划构成侵权。Entresto占诺华销售额约10%，其补充保护证书有效期至2028年，该裁定巩固了公司中期营收预期。
此外，诺华此前公布的二季度业绩大幅超预期，每股收益2.41美元超市场预期的2.13美元，销售额144.1亿美元同样超预期，创新药组合持续放量抵消仿制药冲击。行业层面，制药板块整体走强，默沙东涨11.48%、礼来涨3.64%、辉瑞涨3.28%，板块共振为个股提供上行动能。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.